Park Avenue Securities LLC Has $274,000 Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Park Avenue Securities LLC increased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 23.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,434 shares of the company’s stock after purchasing an additional 2,341 shares during the period. Park Avenue Securities LLC’s holdings in Teva Pharmaceutical Industries were worth $274,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in TEVA. UMB Bank n.a. increased its holdings in shares of Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after purchasing an additional 2,067 shares in the last quarter. Smithfield Trust Co increased its position in Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after buying an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at about $50,000. Claro Advisors LLC acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $52,000. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at approximately $60,000. Institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Christine Fox sold 19,388 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at $744,034.48. This represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $21.74 on Friday. The company has a market capitalization of $24.62 billion, a price-to-earnings ratio of -25.57, a PEG ratio of 1.11 and a beta of 0.73. The business has a 50 day moving average of $19.74 and a 200 day moving average of $18.40. Teva Pharmaceutical Industries Limited has a 1-year low of $11.48 and a 1-year high of $22.80. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TEVA. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Barclays raised their price objective on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. UBS Group increased their price target on Teva Pharmaceutical Industries from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.63.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.